PL3397631T3 - Podstawione 3-azabicyklo[3.1.0]heksany jako inhibitory ketoheksokinazy - Google Patents
Podstawione 3-azabicyklo[3.1.0]heksany jako inhibitory ketoheksokinazyInfo
- Publication number
- PL3397631T3 PL3397631T3 PL16823054T PL16823054T PL3397631T3 PL 3397631 T3 PL3397631 T3 PL 3397631T3 PL 16823054 T PL16823054 T PL 16823054T PL 16823054 T PL16823054 T PL 16823054T PL 3397631 T3 PL3397631 T3 PL 3397631T3
- Authority
- PL
- Poland
- Prior art keywords
- azabicyclo
- hexanes
- substituted
- ketohexokinase inhibitors
- ketohexokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562272598P | 2015-12-29 | 2015-12-29 | |
| US201662423549P | 2016-11-17 | 2016-11-17 | |
| EP16823054.8A EP3397631B1 (en) | 2015-12-29 | 2016-12-16 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
| PCT/IB2016/057728 WO2017115205A1 (en) | 2015-12-29 | 2016-12-16 | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3397631T3 true PL3397631T3 (pl) | 2021-09-20 |
Family
ID=57755415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16823054T PL3397631T3 (pl) | 2015-12-29 | 2016-12-16 | Podstawione 3-azabicyklo[3.1.0]heksany jako inhibitory ketoheksokinazy |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US9809579B2 (pl) |
| EP (1) | EP3397631B1 (pl) |
| JP (1) | JP6503515B2 (pl) |
| KR (1) | KR102073048B1 (pl) |
| CN (1) | CN108473469B (pl) |
| AU (1) | AU2016380920B2 (pl) |
| CA (1) | CA2952466A1 (pl) |
| CL (1) | CL2018001667A1 (pl) |
| CO (1) | CO2018006714A2 (pl) |
| CU (1) | CU24540B1 (pl) |
| CY (1) | CY1124389T1 (pl) |
| DK (1) | DK3397631T3 (pl) |
| EC (1) | ECSP18048517A (pl) |
| ES (1) | ES2871251T3 (pl) |
| GE (1) | GEP20207147B (pl) |
| HK (1) | HK1259073A1 (pl) |
| HR (1) | HRP20210769T1 (pl) |
| HU (1) | HUE054380T2 (pl) |
| IL (1) | IL260330B (pl) |
| LT (1) | LT3397631T (pl) |
| MA (1) | MA43518B1 (pl) |
| MD (1) | MD3397631T2 (pl) |
| MX (1) | MX2018007755A (pl) |
| NI (1) | NI201800072A (pl) |
| PE (1) | PE20181289A1 (pl) |
| PH (1) | PH12018501375A1 (pl) |
| PL (1) | PL3397631T3 (pl) |
| PT (1) | PT3397631T (pl) |
| RS (1) | RS61896B1 (pl) |
| RU (1) | RU2696269C1 (pl) |
| SG (1) | SG11201804363UA (pl) |
| SI (1) | SI3397631T1 (pl) |
| SV (1) | SV2018005709A (pl) |
| TN (1) | TN2018000198A1 (pl) |
| TW (1) | TWI653232B (pl) |
| UA (1) | UA121271C2 (pl) |
| UY (1) | UY37051A (pl) |
| WO (1) | WO2017115205A1 (pl) |
| ZA (1) | ZA201803449B (pl) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054380T2 (hu) | 2015-12-29 | 2021-09-28 | Pfizer | Helyettesített 3-azabiciklo[3.1.0]hexánok mint ketohexokináz inhibitorok |
| KR20230124760A (ko) | 2016-09-02 | 2023-08-25 | 사이클리온 테라퓨틱스, 인크. | 융합된 비시클릭 sGC 자극제 |
| CN109316601B (zh) * | 2017-07-31 | 2021-11-09 | 武汉朗来科技发展有限公司 | 药物组合物及其用途 |
| US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| CR20210110A (es) * | 2018-08-31 | 2021-05-13 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
| TWI714231B (zh) * | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| KR102558308B1 (ko) * | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| CA3127130A1 (en) * | 2019-01-29 | 2020-08-06 | Shandong Xuanzhu Pharma Co., Ltd. | Hexone glucokinase inhibitor and use thereof |
| CA3140972C (en) | 2019-05-20 | 2024-06-18 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN111978296A (zh) * | 2019-05-22 | 2020-11-24 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| TWI750685B (zh) | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| BR112022010599A2 (pt) | 2019-12-10 | 2022-08-16 | Pfizer | Formas sólidas de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico, sal de 1,3-dihidróxi-2-(hidroximetil)propan-2-amina |
| EP4083034A4 (en) * | 2019-12-24 | 2023-12-06 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | ASSOCIATION WITH CHAD-INHIBITING EFFECT |
| CN114846008B (zh) * | 2019-12-25 | 2024-05-28 | 杭州中美华东制药有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
| GB202001856D0 (en) * | 2020-02-11 | 2020-03-25 | Inorbit Therapeutics Ab | Compounds useful in inhibiting ketohexokinase and methods of making and using the same |
| US20230167087A1 (en) * | 2020-02-13 | 2023-06-01 | Eli Lilly And Company | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| JP2021155415A (ja) | 2020-03-27 | 2021-10-07 | ファイザー・インク | ２−［（４−｛６−［（４−シアノ−２−フルオロベンジル）オキシ］ピリジン−２−イル｝ピペリジン−１−イル）メチル］−１−［（２ｓ）−オキセタン−２−イルメチル］−１ｈ−ベンゾイミダゾール−６−カルボン酸またはその薬学的な塩を用いた２型糖尿病、または肥満、または過体重の治療 |
| WO2021215765A1 (ko) | 2020-04-20 | 2021-10-28 | 주식회사 엘지화학 | 3-아자바이사이클로알킬 유도체 및 이를 포함하는 약제학적 조성물 |
| CN111423420A (zh) * | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| CN113754640B (zh) * | 2020-06-03 | 2023-02-14 | 山东轩竹医药科技有限公司 | 氘代的己酮糖激酶抑制剂及其用途 |
| EP4190776A4 (en) * | 2020-07-28 | 2024-02-28 | Shandong Xuanzhu Pharma Co., Ltd. | SALT AND CRYSTAL FORM OF A KETOHEXOCINASE INHIBITOR AND USE THEREOF |
| KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
| CN114181198A (zh) * | 2020-09-15 | 2022-03-15 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类己酮糖激酶抑制剂及其用途 |
| JP2024501507A (ja) | 2020-12-25 | 2024-01-12 | スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド | ケトヘキソキナーゼ阻害剤及びその用途 |
| US20230079863A1 (en) | 2021-03-29 | 2023-03-16 | Gilead Sciences, Inc. | Khk inhibitors |
| KR20220136939A (ko) | 2021-04-01 | 2022-10-11 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2022262841A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 一种螺环化合物的盐型、晶型及其制备方法 |
| BR112024002129A2 (pt) | 2021-08-31 | 2024-04-30 | Pfizer | Formas sólidas de ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico, sal de 1,3-di-hidróxi-2-(hidroximetil)propan-2-amina |
| CN115974851A (zh) * | 2021-10-14 | 2023-04-18 | 华领医药技术（上海）有限公司 | 2-氧代-3-氮杂双环[3.1.0]己烷衍生物 |
| WO2023111817A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid |
| WO2023121378A1 (ko) | 2021-12-24 | 2023-06-29 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
| CN114315494B (zh) * | 2021-12-29 | 2023-09-22 | 苏州楚凯药业有限公司 | 一种(s)-2-甲基氮杂环丁烷盐酸盐的制备方法 |
| WO2023151473A1 (zh) * | 2022-02-09 | 2023-08-17 | 上海研健新药研发有限公司 | 一种khk抑制剂，其制备方法和应用 |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2024084360A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980350A (en) | 1988-02-25 | 1990-12-25 | Merck & Co., Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| DE4208254A1 (de) | 1992-03-14 | 1993-09-16 | Hoechst Ag | Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| RU2001103044A (ru) | 1998-07-06 | 2003-08-10 | Бристол-Маерс Сквибб Ко. (Us) | Бенилсульфонамиды в качестве двойных антагонистов ангиотензиновых эндотелиновых рецепторов |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| HUP0303376A3 (en) | 2001-02-28 | 2007-08-28 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof |
| EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
| EP1753748B1 (en) | 2004-05-12 | 2009-07-29 | Pfizer Products Inc. | Proline derivatives and their use as dipeptidyl peptidase iv inhibitors |
| EP1753766A1 (en) | 2004-05-25 | 2007-02-21 | Pfizer Products Inc. | Tetraazabenzo(e)azulene derivatives and analogs thereof |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| NL2000581C2 (nl) | 2006-04-20 | 2008-01-03 | Pfizer Prod Inc | Aangecondenseerde fenylamidoheterocyclische verbindingen. |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2008024902A2 (en) | 2006-08-23 | 2008-02-28 | University Of Florida Research Foundation, Inc. | Targeting of fructokinase as therapy for cardiovascular disease, metabolic syndrome, and renal disease |
| EA200900613A1 (ru) | 2006-11-29 | 2009-10-30 | Пфайзер Продактс Инк. | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз |
| US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
| US8008483B2 (en) * | 2007-10-11 | 2011-08-30 | GlaxoSmithKline, LLC | sEH inhibitors and their use |
| US8318762B2 (en) | 2008-05-28 | 2012-11-27 | Pfizer Inc. | Pyrazolospiroketone acetyl-CoA carboxylase inhibitors |
| US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| EP2318370A1 (en) | 2008-07-29 | 2011-05-11 | Pfizer Inc. | Fluorinated heteroaryls |
| CA2732618A1 (en) * | 2008-07-30 | 2010-02-04 | Ranbaxy Laboratories Limited | Pyrrole carboxylic acid derivatives as antibacterial agents |
| CN102149717B (zh) | 2008-08-28 | 2014-05-14 | 辉瑞大药厂 | 二氧杂-双环[3.2.1]辛烷-2，3，4-三醇衍生物 |
| WO2010086820A1 (en) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof |
| KR101295937B1 (ko) | 2009-03-11 | 2013-08-14 | 화이자 인코포레이티드 | 글루코카이네이즈 억제제로서 사용되는 벤조푸라닐 유도체 |
| EP2406230A1 (en) | 2009-03-11 | 2012-01-18 | Pfizer Inc. | Substituted indazole amides and their use as glucokinase activators |
| JP2012520868A (ja) | 2009-03-20 | 2012-09-10 | ファイザー・インク | ３−オキサ−７−アザビシクロ［３．３．１］ノナン |
| MX2011010200A (es) | 2009-04-08 | 2011-10-14 | Actelion Pharmaceuticals Ltd | 6-(3-aza-biciclo[3.1.0]hex-3-il)-2fenil-pirimidinas como antagonistas del receptor de adenosina 5'-difosfato (adp). |
| US20120052130A1 (en) | 2009-05-08 | 2012-03-01 | Pfizer Inc. | Gpr 119 modulators |
| CA2759843A1 (en) | 2009-05-08 | 2010-11-10 | Pfizer Inc. | Gpr 119 modulators |
| BRPI1014636A2 (pt) | 2009-06-05 | 2016-04-05 | Pfizer | moduladores de gpr 119 |
| WO2011005611A1 (en) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Neuromedin u receptor agonists and uses thereof |
| KR101686913B1 (ko) | 2009-08-13 | 2016-12-16 | 삼성전자주식회사 | 전자기기에서 이벤트 서비스 제공 방법 및 장치 |
| WO2011133750A1 (en) | 2010-04-22 | 2011-10-27 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| WO2012019188A2 (en) * | 2010-08-06 | 2012-02-09 | The Regents Of The University Of Colorado, A Body Corporate | Methods and compositions for the inhibition of fructokinase |
| CN102432598A (zh) * | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | 三环化合物、其制备方法及其在医药上的应用 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| KR102389968B1 (ko) | 2014-02-11 | 2022-04-25 | 알닐람 파마슈티칼스 인코포레이티드 | 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법 |
| HUE054380T2 (hu) * | 2015-12-29 | 2021-09-28 | Pfizer | Helyettesített 3-azabiciklo[3.1.0]hexánok mint ketohexokináz inhibitorok |
-
2016
- 2016-12-16 HU HUE16823054A patent/HUE054380T2/hu unknown
- 2016-12-16 UA UAA201807242A patent/UA121271C2/uk unknown
- 2016-12-16 AU AU2016380920A patent/AU2016380920B2/en active Active
- 2016-12-16 DK DK16823054.8T patent/DK3397631T3/da active
- 2016-12-16 ES ES16823054T patent/ES2871251T3/es active Active
- 2016-12-16 PL PL16823054T patent/PL3397631T3/pl unknown
- 2016-12-16 GE GEAP201614820A patent/GEP20207147B/en unknown
- 2016-12-16 PE PE2018001204A patent/PE20181289A1/es unknown
- 2016-12-16 LT LTEP16823054.8T patent/LT3397631T/lt unknown
- 2016-12-16 CN CN201680077234.3A patent/CN108473469B/zh active Active
- 2016-12-16 TN TNP/2018/000198A patent/TN2018000198A1/en unknown
- 2016-12-16 JP JP2018533924A patent/JP6503515B2/ja active Active
- 2016-12-16 CU CU2018000046A patent/CU24540B1/es unknown
- 2016-12-16 KR KR1020187018089A patent/KR102073048B1/ko active IP Right Grant
- 2016-12-16 PT PT168230548T patent/PT3397631T/pt unknown
- 2016-12-16 EP EP16823054.8A patent/EP3397631B1/en active Active
- 2016-12-16 WO PCT/IB2016/057728 patent/WO2017115205A1/en active Application Filing
- 2016-12-16 MD MDE20181083T patent/MD3397631T2/ro not_active IP Right Cessation
- 2016-12-16 MA MA43518A patent/MA43518B1/fr unknown
- 2016-12-16 RS RS20210654A patent/RS61896B1/sr unknown
- 2016-12-16 RU RU2018123528A patent/RU2696269C1/ru active
- 2016-12-16 SG SG11201804363UA patent/SG11201804363UA/en unknown
- 2016-12-16 US US15/381,295 patent/US9809579B2/en active Active
- 2016-12-16 MX MX2018007755A patent/MX2018007755A/es active IP Right Grant
- 2016-12-16 SI SI201631206T patent/SI3397631T1/sl unknown
- 2016-12-22 CA CA2952466A patent/CA2952466A1/en active Pending
- 2016-12-27 UY UY0001037051A patent/UY37051A/es not_active Application Discontinuation
- 2016-12-28 TW TW105143483A patent/TWI653232B/zh active
-
2017
- 2017-10-11 US US15/729,885 patent/US10174007B2/en active Active
-
2018
- 2018-05-24 ZA ZA2018/03449A patent/ZA201803449B/en unknown
- 2018-06-13 SV SV2018005709A patent/SV2018005709A/es unknown
- 2018-06-19 CL CL2018001667A patent/CL2018001667A1/es unknown
- 2018-06-25 NI NI201800072A patent/NI201800072A/es unknown
- 2018-06-26 PH PH12018501375A patent/PH12018501375A1/en unknown
- 2018-06-27 EC ECSENADI201848517A patent/ECSP18048517A/es unknown
- 2018-06-27 CO CONC2018/0006714A patent/CO2018006714A2/es unknown
- 2018-06-28 IL IL260330A patent/IL260330B/en unknown
- 2018-12-06 US US16/211,283 patent/US20190106412A1/en not_active Abandoned
-
2019
- 2019-01-29 HK HK19101573.2A patent/HK1259073A1/zh unknown
-
2020
- 2020-01-16 US US16/744,283 patent/US10787438B2/en active Active
- 2020-08-21 US US16/999,295 patent/US10988463B2/en active Active
-
2021
- 2021-03-23 US US17/209,780 patent/US11634410B2/en active Active
- 2021-05-06 CY CY20211100385T patent/CY1124389T1/el unknown
- 2021-05-13 HR HRP20210769TT patent/HRP20210769T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1259073A1 (zh) | 作為己酮糖激酶抑制劑的被取代的3-氮雜雙環[3‧1‧0]己烷 | |
| HK1258275A1 (zh) | 用於調節血管緊張素原表達的化合物和方法 | |
| EP3380101A4 (en) | EIF4-A INHIBITOR COMPOUNDS AND ASSOCIATED METHODS | |
| IL252828A0 (en) | Piperidine derivative compounds suppressing hdac1/2 preparations containing them and their uses | |
| PT3552017T (pt) | Compostos úteis como inibidores de ripk1 | |
| EP3453900A4 (en) | BOLT | |
| EP3193609A4 (en) | Substituted pyrrolidine carboxamide compounds | |
| EP3368539A4 (en) | SUBSTITUTED INDAZOLE COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | |
| EP3315626A4 (en) | Bolt | |
| EP3094798A4 (en) | Padlock cylinder retention | |
| HRP20180933T1 (hr) | 5-oksa-2-azabiciklo[2.2.2]oktan-4-il i 5-oksa-2-azabiciklo[2.2.1]heptan-4-il derivati kao taar1 modulatori | |
| EP3097084A4 (en) | New kallikrein 7 inhibitors | |
| EP3237399A4 (en) | Compounds, compositions and methods | |
| EP3240540A4 (en) | Hdac1,2 inhibitors and methods of using the same | |
| EP3540244A4 (en) | BOLT | |
| EP3604834A4 (en) | BOLT | |
| AU2015900969A0 (en) | Improved Objects Type 26 | |
| AU2015901453A0 (en) | Improved Objects 3. 4. 15... | |
| AU2014904695A0 (en) | Improved Objects Type 10 11 14 | |
| AU2014904344A0 (en) | Improved Objects Type 24 10 14 | |
| AU2014904199A0 (en) | Improved Objects Type 8 10 14 | |
| AU2014904079A0 (en) | Improved Objects Type 245 | |
| AU2014903959A0 (en) | Improved Objects Type 24 | |
| AU2014903577A0 (en) | Improved Objects Type 244 | |
| AU2014903470A0 (en) | Improved Objects Type 24 |